Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

• Published in: Orphanet journal of rare diseases 2019-08, Vol.14 (1), p.186-9, Article 186
• Main Authors: Vanhoorne, V, Peeters, E, Van Tongelen, I, Boussery, K, Wynendaele, E, De Spiegeleer, B, Remon, J P, Vervaet, C
• Format: Article
• Language: English
• Subjects: Arginine; Arginine - analysis; Backup software; Belgium; Carnitine; Carnitine - analysis; Drug compounding; Drug Compounding - methods; Drug therapy; Excipients - analysis; High performance liquid chromatography; Humans; Laws, regulations and rules; Levocarnitine; Marketing; Methods; Orphan active ingredients; Patient care; Pharmaceutical compounding; Pharmacists; Phenylbutyrates - analysis; Phosphates; Primaquine; Primaquine - analysis; Pyridoxal Phosphate - analysis; Rare Diseases; Sodium benzoate; Sodium Benzoate - analysis
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-019-1154-x

Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages. Additionally, it allows customized therapy for patients with rare diseases. However, standardized compounding formulas and procedures, and monographs are required to ensure the patients' safety. Standardized formulas and compounding procedures were developed for seven orphan active ingredients (L-arginine, sodium benzoate, sodium phenylbutyrate, L-carnitine, chenodesoxycholic acid, primaquine phosphate, pyridoxal phosphate) and one non-orphan molecule (sodium perchlorate) regularly compounded by hospital pharmacists for extemporaneous use. The stability of these formulations was evaluated over 3 months at refrigerated (5 °C) and standard storage conditions (25 °C/60%RH) using HPLC-based assays and a suitable shelf life was assigned to the formulations. Additionally, suitable analytical methods for quality control of formulations of pyridoxal phosphate and sodium perchlorate were developed as monographs for these components were not available in the European Pharmacopeia or United States Pharmacopeia. Availability of compounding formulas and protocols, as well as stability information, for orphan active ingredients can improve patients' access to treatment for rare diseases. Such data were collected for seven orphan active ingredients to treat patients with rare diseases when no other treatment is available. More efforts are needed to develop standardized formulas and compounding procedures for additional orphan active ingredients whose clinical efficacy is well-known but which are not available as products with a marketing authorization. Additionally, a legal framework at EU level is required to enable the full potential of pharmaceutical compounding for orphan active ingredients.